Update on Biologics for Psoriasis in Clinical Practice

Abstract

Biologics have impacted the clinical management of moderate to severe psoriasis. This review article highlights new data findings from phase 3 clinical trials (N=8) published between May 2020 and February 2021. Data on the efficacy of US Food and Drug Administration–approved biologics for treating psoriasis affirms durable skin clearance in the presence of comorbidities and after treatment gaps. This article aims to provide clinicians with up-to-date knowledge on biologic performance focusing on skin disease clearance, time to skin disease clearance, loss of response and relapse, and treatment-emergent adverse events (TEAEs). Recent trial data in this review focus on treatment with IL-17A inhibitors and IL-23 inhibitors.